Synthesis and evaluation of analgesic, anti-inflammatory and antioxidant activities of new 6-acyl-3-alkyl-5-methyl-2(3H)-benzoxazolones

A new series of 6-acyl-3-alkyl-5-methyl-2(3H)-benzoxazolones have been obtained starting from 5-methyl-2(3H)-benzoxazolone. All the compounds have been characterized by IR, 1H-NMR and mass spectroscopy. The new compounds were screened for analgesic and anti-inflammatory activities and ulcerogenic effect. The in vitro antioxidant capacity of the synthesized compounds were tested by the nitric oxide radical scavenging assay. Most of the compounds showed antiinflammatory activity. Among them, 3-[4-(4-fluorophenyl)piperazinomethyl] -6-(3-chlorobenzoyl)-5-methyl-2(3H)-benzoxazolone (3j) was found more potent than the reference drug indometacin (CAS 53-86-1) with 41.66% decrease in edema. Compared with the control, some of the compounds exhibited analgesic effects. Similar to the anti-inflammatory activity results, compound 3j showed the highest analgesic profile with 48.56% inhibition. No active hemorragic focus was observed in the microscopic evaluation in the ulcerogenic effect studies of the tested compounds. 6-(3-Chlorobenzoyl)-5-methyl-2(3H)-benzoxazolone (2b) and 3-[4-(4-fluorophenyl-piperazino)methyl]-6-(3-chlorobenzoyl)-5-methyl-2(3H)-benzoxazolone (3j) showed nearly maximum antioxidant activity compared to ascorbic acid (CAS 50-81-7) with IC50 values of 27.6 and 30.1 microg/mL, respectively.     

Endometrial flushing αVβ3 integrin,glycodelin and PGF2α levels for evaluating endometrial receptivity in women with polycystic ovary syndrome,myoma uteri and endometrioma

The aim of this cross-sectional study is to compare endometrial flushing fluid levels of α_Vβ₃ integrin, glycodelin and PGF2α during the midluteal phase of the menstrual cycle of women with polycystic ovary syndrome (PCOS, n?=?20), myoma uteri (n?=?20) and endometrioma (n?=?19) with the healthy controls (n?=?20). After collecting samples at the midluteal phase of ovulatory volunteers and storing them at ?80?°C, α_Vβ₃ integrin, glycodelin and PGF2α levels were analyzed using ELISA. The mean ages of the groups were 28.90?±?5.45, 37.25?±?2.73, 32.84?±?6.62 and 32.15?±?5.18 in PCOS, myoma uteri, endometrioma and control groups, respectively. The α_Vβ₃ integrin level (ng/ml) was statistically significantly higher in endometrioma group (9.70?±?1.72, p?0.05) as compared to myoma uteri and control groups. Similarly, glycodelin level (ng/ml) was significantly higher in endometrioma group (341.04?±?93.32) than PCOS (p?0.01), myoma uteri (p?0.001) and healthy subjects (p?0.001). Moreover, PGF2α level (350.04?±?464.50?ng/ml) was significantly higher in PCOS group relative to myoma uteri (p?0.001), endometrioma (p?0.05) and control (p?0.05) groups. In conclusion, α_Vβ₃ integrin level was significantly higher in endometrioma subjects than those with myoma uteri and control groups; glycodelin level was significantly higher in endometrioma group than other three groups, and lastly, PCOS patients had significantly higher PGF2α levels than those patients with myoma uteri, endometrioma and controls.     

A Comprehensive Surgical Procedure in Conservative Management of Placenta Accreta: A Case Series

We aimed to present a combined surgical procedure in conservative treatment of placenta accreta based on surgical outcomes in our cohort of patients. The study was designed as a prospective cohort series study. The setting involved two education and research hospitals in Turkey. This study included 12 patients with placenta accreta who were prenatally diagnosed and managed.We offered the patients the choice of conservative or nonconservative treatment. We then offered 2 choices for patients who had preferred conservative treatment, leaving the placenta in situ as is the classical procedure, or our surgical procedure. One patient preferred nonconservative treatment, the others opted for our procedure.We evaluated demographic and obstetric characteristics of patients, sonographic and operative parameters of patients, and surgical outcomes.We operated on 11 patients using this surgical procedure that we have developed for placenta accreta cases. We found that there was no need for hysterectomy in any patient, and we preserved the uterus for all of these patients. No patient presented any septic complication or secondary vaginal bleeding.Our surgical procedure seems to be effective and useful in the conservative treatment of placenta accreta.     

Nasal bone to nasal tip length ratio for describing nasal bone hypoplasia and predicting trisomy 21

IntroductionFetal nasal bone hypoplasia has been proven to be a strong marker for trisomy 21 during second trimester ultrasonography. Rather than evaluating the nasal bone hypoplasia according to the nomograms, it may be possible to evaluate it with a more practical and specific method.Material and methodsRetrospectively collected data were provided from the saved and stored patient data between 2012 and 2017. Nasal bone length and nasal tip length were measured and the ratio was calculated. The ratio ≤ 1/3 was defined as the threshold ratio for the definition of the marker. Nasal bone nasal tip length (NB/NL) ratio values were compared among groups with trisomy 21 and euploid fetuses.ResultsA total of 59 fetuses had trisomy 21 and 2304 euploid fetuses were included in the study. The ratio of nasal bone to nasal tip length was 1/3 and below in 21/59 (35.5%) of fetuses with trisomy 21 whereas this ratio was 31/2304 (1.3%) in euploid fetuses. The difference was statistically significant (p < 0.001). Sensitivity, specificity, positive likelihood ratio and negative likelihood ratio of nasal bone/nasal tip ratio ≤ 1/3 were 35.5%, 98.6%, 26.4 and 0.6 for Down syndrome, respectively.ConclusionsThis study suggested that the nasal bone to nasal tip length ratio may be a new promising and practical sonographic marker in the second trimester genetic sonography. Although its sensitivity is not high, it seems to be more practical and specific than the evaluation of fetal nasal bone length.     

Prenatal diagnosis of type I sacrococcygeal teratoma and its management

PURPOSE: To report a case of type I sacrococcygeal teratoma (SCT) diagnosed prenatally and managed surgically successfully in the neonatal period. CASE REPORT: A gravida 2, para 1, woman at 32 week's gestation was referred for suspected fetal anomaly. On US a 14 x 12 cm mass with solid and cystic components was detected in the sacral region of the fetus. On MRI the tumor had no apparent intrapelvic or intraabdominal extent, indicating type I SCT. Cesarean section was performed at 34 weeks' gestation due to signs of deteriorating high output cardiac compromise in the fetus. In the neonatal period stabilization of the infant was achieved. At age ten days the mass was successfully excised surgically. CONCLUSION: Prenatal determination of SCT, follow-up with sonography, time, and mode of delivery are indicative factors for prognosis in SCT.     

Effect of tubal ligation on ovarian reserve and the ovarian stromal blood supply

AIM: Our aim was to evaluate possible adverse effects of tubal ligation on ovarian reserve and ovarian stromal vascular support. METHODS: Ninety-one women who underwent tubal ligation, using a modified Pomeroy technique, were studied. The main outcome measurements were serum follicle stimulating hormone, luteinising hormone and oestradiol levels, ovarian volume, number of antral follicles and Doppler study of ovarian stromal artery on the third day of the menstrual cycle immediately before, 1 month and 12 months after the surgical intervention. RESULTS: Statistically significant elevation of follicle stimulating hormone levels was observed at 1 and 12 months after tubal ligation (P < 0.05). CONCLUSION: Doppler flow studies of the ovarian stromal arteries showed that there were no significant differences before and after tubal ligation.